Synta Pharmaceuticals (SNTA) Announces Publication of Clinical and Non-Clinical Results Demonstrating Unique Anti-angiogenic Effects of Ganetespib
7/17/2013 9:52:21 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today publication of results from in vitro, in vivo, and translational clinical studies demonstrating the effect of ganetespib on the ability of tumors to grow new blood vessels (angiogenesis). The paper appeared in the July 10, 2013, online issue of Angiogenesis. Ganetespib, a selective inhibitor of the Hsp90 chaperone protein in development by Synta, is being evaluated in over 20 clinical trials for different types of cancer, including a pivotal Phase 3 trial in non-small cell lung cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by